The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study
Open accessAbstract
Objective : To quantify the association between olanzapine and diabetes. Design : Population based nested case-control study. Setting : United Kingdom based General Practice Research Database comprising 3.5 million patients followed between 1987 and 2000. Participants : 19 637 patients who had been diagnosed as having and treated for schizophrenia. 451 incident cases of diabetes were matched with 2696 controls. Main outcome measures : Diagnosis and treatment of diabetes. Results : Patients taking olanzapine had a significantly increased risk of developing diabetes than non-users of antipsychotics (odds ratio 5.8, 95% confidence interval 2.0 to 16.7) and those taking conventional antipsychotics (4.2, 1.5 to 12.2). Patients taking risperidone had a non-significant increased risk of developing diabetes than non-users of antipsychotics (2.2, 0.9 to 5.2) and those taking conventional antipsychotics (1.6, 0.7 to 3.8). Conclusion : Olanzapine is associated with a clinically important and significant increased risk of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, those taking olanzapine require greater monitoring because of an increase in risk of type 2 diabetes associated with this medication (88).”
From Psychosocial care for people with diabetes: a position statement of the American Diabetes Association (2016) · cites this paper as [88]
In the citing paper
“In addition, those taking second-generation (atypical) antipsychotics, such as olanzapine, require greater monitoring because of an increase in risk of type 2 diabetes associated with this medication (418-420).”
From 5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023 (2023) · cites this paper as [418]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Logistic Regression: A Self-Learning Text.
Selvin, S., & Kleinbaum, D. G. (1996) · Journal of the American Statistical Association · doi:10.2307/2291427 · Cited by 1,628
The UK General Practice Research Database
Walley, T., & Mantgani, A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)04248-7 · Cited by 624
Novel antipsychotics and new onset diabetes
Wirshing, D. A., Spellberg, B. J., Erhart, S. M., Marder, S. R., & Wirshing, W. C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00100-0 · Cited by 407
Valproate, lamotrigine, and insulin‐mediated risks in women with epilepsy
Isojärvi, J. I. T., Rättyä, J., Myllylä, V. V., Knip, M., Koivunen, R. M., Pakarinen, A., Tekay, A., & Tapanainen, J. S. (1998) · Annals of Neurology · doi:10.1002/ana.410430406 · Cited by 342
The General Practice Research Database
Wood, L., & Martínez, C. (2004) · Drug Safety · doi:10.2165/00002018-200427120-00004 · Cited by 330
Melkersson, K. I., Hulting, A., & Brismar, K. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1006 · Cited by 300
THE METABOLIC EFFECTS OF EPINEPHRINE AND RELATED AMINES
Ellis, S. (1956) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06998-4 · Cited by 288
Meyer, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0509 · Cited by 267
Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study
Coulter, D. M., Bate, A., Meyboom, R. H. B., Lindquist, M., & Edwards, I. R. (2001) · BMJ · doi:10.1136/bmj.322.7296.1207 · Cited by 234
Accuracy of diagnosis of psychosis on general practice computer system.
Nazareth, I., King, M., Haines, A., Rangel, L., & Myers, S. (1993) · BMJ · doi:10.1136/bmj.307.6895.32 · Cited by 196
The General Practice Research Database. Scientific and Ethical Advisory Group
Lawson, D. H. (1998) · QJM · doi:10.1093/qjmed/91.6.445 · Cited by 176
Olanzapine-Induced Ketoacidosis With Diabetes Mellitus
Lindenmayer, J., & PATEL, R. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1471 · Cited by 169
Pharmacologic treatment of schizophrenia
Kane, J. M. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00059-1 · Cited by 155
Phenothiazines and Diabetes in Hospitalized Women
Thonnard‐Neumann, E. (1968) · American Journal of Psychiatry · doi:10.1176/ajp.124.7.978 · Cited by 145
Melkersson, K. I., Hulting, A., & Brismar, K. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1112 · Cited by 125
Holbrook, T. L., Barrett-Connor, E. L., & Wingard, D. L. (1989) · PubMed · Cited by 122
Hyperglycemia Associated With Olanzapine
Fertig, M. K., Brooks, V. G., Shelton, P. S., & English, C. W. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n1208c · Cited by 110
Olanzapine-Induced Glucose Dysregulation
Bettinger, T. L., Mendelson, S. C., Dorson, P. G., & Crismon, M. L. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19327 · Cited by 104
Ober, S. K., Hudak, R., & Rusterholtz, A. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.6.970 · Cited by 93
Howarth, P. H., Mb, E., & Holgate, S. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb05013.x · Cited by 88
Diabetes as a result of atypical anti‐psychotic drugs – a report of three cases
Rigalleau, V., Gatta‐Cherifi, B., Bonnaud, S., Masson, M., Bourgeois, M.-L., Vergnot, V., & Gin, H. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00296.x · Cited by 80
Effect of duration of low-dose oral contraceptive administration on carbohydrate metabolism
Wynn, V. (1982) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(16)32481-4 · Cited by 74
Biswas, P. N., Wilton, L., Pearce, G. L., Freemantle, S. N., & Shakir, S. (2001) · Journal of Psychopharmacology · doi:10.1177/026988110101500405 · Cited by 67
Goodall, E., Oxtoby, C., Richards, R. P., Watkinson, G., Brown, D., & Silversonte, T. (1988) · The British Journal of Psychiatry · doi:10.1192/bjp.153.2.208 · Cited by 61
Analysis of Matched Data Using Logistic Regression
Kleinbaum, D. G., & Klein, M. (2010) · Statistics for biology and health · doi:10.1007/978-1-4419-1742-3_11 · Cited by 48
Psychotropic drug induced weight gain: mechanisms and management.
Bernstein, J. G. (1988) · PubMed · Cited by 42
Drugs of the Psychopharmacological Revolution in Clinical Psychiatry
Lieberman, J. A., Golden, R., Stroup, T. S., & McEvoy, J. P. (2000) · Psychiatric Services · doi:10.1176/appi.ps.51.10.1254 · Cited by 30
Pharmacotherapy of Type 2 Diabetes Mellitus
Rendell, M., & Kirchain, W. R. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19171 · Cited by 30
Analysis of Matched Data Using Logistic Regression
Kleinbaum, D. G. (1994) · Springer eBooks · doi:10.1007/978-1-4757-4108-7_8 · Cited by 9
Flagged first, then by citations
Research works printed but not linked: 2
- Caro, 2000, Atypical antipsychotics and the risk of developing diabetes. International Society for Pharmacoeconomics and Outcomes Research European meeting, Belgium, 2000., Value Health, 3, MH2
- 10.1176/appi.ajp.124.7.978 · DOI
Cited by
Sorted by citations
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Second-Generation (Atypical) Antipsychotics and Metabolic Effects
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,352
Schizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070
Young-Hyman, D., de Groot, M., Hill-Briggs, F., Gonzalez, J. S., Hood, K., & Peyrot, M. (2016) · Diabetes Care · doi:10.2337/dc16-2053 · Cited by 1,072
Mood disorders in the medically ill: scientific review and recommendations
Evans, D. L., Charney, D. S., Lewis, L., Golden, R. N., Gorman, J. M., Krishnan, K. R. R., Nemeroff, C. B., Bremner, J. D., Carney, R. M., Coyne, J. C., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.001 · Cited by 1,071
Metadata
- Authors
- Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R.
- Affiliations
- University of Maryland, Baltimore (US)
- Corresponding author
- Koro, Carol E
- ORCID
- Kreyenbuhl, Julie
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2002-08-03
- Volume
- 325
- Issue
- 7358
- Pages
- 243
- ISSN
- 0007-1447 (ISSN-L)
- 0959-8138
- 1468-5833
- PMC
- PMC117636
- OpenAlex
- W2160802754
- Cited by
- 421
- References
- 30
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 8 · 2020: 6 · 2019: 3 · 2018: 7 · 2017: 8 · 2016: 8 · 2015: 8 · 2014: 5 · 2013: 10 · 2012: 9
- FWCI
- 37.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.bmj.com/company/legal-information/terms-conditions/legal-information/tdm-licencepolicy (tdm)
- Locations
- BMJ (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- olanzapine, risperidone, schizophrenia, diabetes risk, antipsychotic drugs, adverse drug reactions, typical antipsychotics, type 2 diabetes
- MeSH terms
- Olanzapine, Adult, Aged, Benzodiazepines, Diabetes Mellitus, Female, Follow-Up Studies, Humans, Male, Middle Aged, Pirenzepine, Regression Analysis, Risk Factors, Schizophrenia, Antipsychotic Agents, Cohort Studies, Odds Ratio, Case-Control Studies, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
